Form 4: 10x Genomics CEO Sells Shares Under 10b5-1 Plan

10x Genomics CEO Serge Saxonov reported sales of Class A Common Stock totaling 16,152 shares and a gift of 2,750 shares under a pre-arranged 10b5-1 trading plan.

Summary

• Serge Saxonov, Chief Executive Officer and Director of 10x Genomics, Inc. (TXG), reported transactions involving Class A Common Stock.
• On March 2, 2026, Saxonov sold 14,292 shares at a weighted average price of $22.669 per share.
• On the same date, an additional 1,860 shares were sold at a weighted average price of $23.1781 per share.
• On March 3, 2026, Saxonov gifted 2,750 shares with a transaction price of $0.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted on November 29, 2025.
• Following these transactions, Saxonov directly beneficially owns 1,200,917 shares of Class A Common Stock.
• Additionally, Saxonov indirectly holds 27 shares via the Andromeda Trust, 213,250 shares via the Y/S Descendants' Trust, and 58,000 shares via the Y/S Pot Trust, for which he serves as trustee.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative signal due to insider selling, though mitigated by the fact it was executed under a pre-arranged 10b5-1 plan, indicating planned diversification rather than a reaction to new information.

Negatives

• CEO Serge Saxonov sold a total of 16,152 shares of Class A Common Stock.
• The sales occurred at weighted average prices of $22.669 and $23.1781 per share.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider selling, even under a Rule 10b5-1 plan, is a routine disclosure for executives managing personal portfolios and diversifying holdings, particularly in the biotechnology and life sciences tools sector where executive compensation often includes significant equity grants. These pre-arranged plans are designed to allow insiders to sell shares without concerns about insider trading, providing transparency to the market.

Stakeholder Impact

• Shareholders: May interpret the insider selling as a slight negative signal, potentially impacting short-term sentiment, though the 10b5-1 plan mitigates this.

Key Dates

Recommendation

While the CEO's sale of shares under a Rule 10b5-1 plan is a pre-scheduled event for personal financial management and diversification, it still represents a reduction in insider holdings. Without additional company-specific news or broader market context, this transaction alone does not warrant a strong buy or sell recommendation. Investors should hold and monitor future company performance and insider activity.

Keywords

10x Genomics, TXG, Serge Saxonov, Insider Trading, CEO Stock Sale, Form 4, 10b5-1 Plan, Beneficial Ownership